



\*Gallo, Young, Fourtounis et al., 2022, Nature 604(7907):749-756

## **Preclinical development of PKMYT1 and WEE1 inhibitor combinations**

## David Gallo<sup>1</sup>, Fenil Shah<sup>1</sup>, Rino Stocco<sup>1</sup>, Cynthia Bernier<sup>1</sup>, Jimmy Fourtounis<sup>1</sup>, Ariya Shiwram<sup>1</sup>, Rosie Kryczka<sup>1</sup>, Marc L. Hyer<sup>2</sup>, Jordan T.F. Young<sup>1</sup>, Anne Roulston<sup>1</sup>, C. Gary Marshall<sup>2</sup>, Michal Zimmermann<sup>1</sup>, Stephen J. Morris<sup>1</sup> and Michael Zinda<sup>2</sup>

<sup>1</sup>Repare Therapeutics, St-Laurent, QC, Canada, <sup>2</sup>Repare Therapeutics, Cambridge, MA, USA

Poster # A023



code for this and other Repare ANE presentations.